Food and Drug Administration

Oncologic Drugs Advisory Committee

December 13, 1999

Slides

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Targretin® Capsules 75mg Bexarotene, Ligand Pharmaceuticals, Inc.  pdf

FDA Medical Officer Review Targretin® (Bexarotene) 75mg Capsules Ligand Pharmaceuticals, Inc., Dr. Oluwole Odujinrin, MD  htm  ppt

Introduction NDA 20-449/SE011 Taxotere® (docetaxel) for Injection Concentrate, Dr. Philip Chaikin, PharmD, MD, Rhône-Poulenc Rorer Pharmaceuticals  htm  ppt

NDA 20-449 SE-011 Docetaxel, FDA Review  htm  ppt